Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million
March 14, 2023 at 7:52:13 AM
Livzon, a diversified Guangdong pharma, entered a $127.5 agreement for China rights to a gastroesophageal reflux disease (GERD) therapy from Onconic Therapeutics of Korea. Onconic will receive an upfront payment of $15 million and up to $112.5 million in milestones plus royalties on sales. Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have exclusive rights to Zastaprazan in China, Taiwan, Hong Kong and Macau.
- CHINABIO TODAY -
About Collabrium Partners
Collabrium Partners is a Chinese leading independent investment banking firm focused on providing financial advisories on mergers & acquisitions, strategic planning, restructuring, private placement, independent opinions to corporations, financial institutions, public service agencies, and others.
For more information, please visit www.collabrium.com